• 14Aug


    Image Source:www.ex-astris-scientia.org

    Rutherford-Appleton Laboratories have developed one of the World´s largest imagers that could form the heart of future medical scanners. The new technology will allow doctors to produce more sensitive and faster images of the human body at a lower-cost to the healthcare profession.

    The innovative technology, which has been developed as part of the £4.5m Basic Technology MI-3 Consortium, will help in providing instant analysis of medical screening tests and the early detection of cancer.

    Easier to use and faster than the imagers used in current body scanners, and with very large active pixel sensors with an imaging area of approximately 6cm square, the technology has been specifically developed to meet demanding clinical applications such as x-ray imaging and mammography. This silicon imager is about 15 times larger in area than the latest Intel processors.

    The next step of the project is to produce wafer-scale imagers which can produce images that approach the width of the human torso. This will eliminate the need for expensive and inefficient lenses and so enable lower-cost, more sensitive and faster medical imaging systems. Very large active pixel sensors could soon be making a major impact on medical imaging by further reducing the need for the old technology of film. The UK is a World-lead in such sensors for scientific and medical applications and this is a lead that UK intends to maintain.

  • 20Jan

    heart1.jpg
    The results of a recent study has shown that heart-failure patients who are given AstraZeneca’s Crestor and standard drugs are just as likely to have heart attacks and strokes or die of cardiovascular problems as those on standard therapy alone.

    AstraZeneca
    has hoped to establish Crestor as the first cholesterol-lowering statin to show clear benefits in treating elderly patients with the chronic heart condition.

    Results of a 5,000-patient study showed Crestor was no better than a placebo, although it did cut levels of “bad” LDL cholesterol and C-reactive protein and reduced hospitalizations for cardiovascular causes. AstraZeneca said that the study had been “novel and challenging” and, though unsuccessful, had established Crestor’s safety in heart-failure patients.

    (Source)

Bad Behavior has blocked 68 access attempts in the last 7 days.